Prediction of antiarrhythmic therapy effectiveness in children
https://doi.org/10.15829/1560-4071-2019-7-75-82
Abstract
Aim. To optimize treatment tactics in children with arrhythmias based on the evaluation and prediction of the therapy efficacy.
Material and methods. Prospective cohort study was performed from 2007 to 2017 A total of 100 patients aged 0 to 7 years with different types of significant arrhythmias received prophylactic antiarrhythmic therapy. Data of medical history, 12-lead electrocardiography (ECG), Holter ECG monitoring, and echocardiography were studied. To verify electrophysiological variant of tachycardia, some patients underwent transesophageal electrophysiologic study.
Results. The study showed that antiarrhythmic drug therapy was most efficacious in patients till one year old without signs of arrhythmogenic cardiomyopathy (ACM). Older age of children, the presence of pronounced ACM manifestations are factors that increase the risk of ineffective AAT. Based on the data obtained, a multifactor model was developed to predict the effectiveness of prolonged antiarrhythmic therapy.
Conclusion. The study showed that age and intracardiac hemodynamic status affected the efficacy of antiarrhythmic therapy. Proposed model allowed to avoid unnecessary prolonged pharmacological load and to timely administer other methods of treatment in case when ineffective result of the antiarrhythmic therapy was predicted.
About the Authors
L. I. Svintsova
Research Institute of Cardiology, Tomsk National Research Medical Center
Russian Federation
Competing Interests: not
Russian Federation
Competing Interests: not
O. Yu. Dzhaffarova
Research Institute of Cardiology, Tomsk National Research Medical Center
Russian Federation
Competing Interests: not
Russian Federation
Competing Interests: not
I. V. Plotnikova
Research Institute of Cardiology, Tomsk National Research Medical Center; 2 Siberian State Medical University
Russian Federation
Competing Interests: not
Russian Federation
Competing Interests: not
References
1. Riggs TW, Byrd JA, Weinhouse E. Recurrence risk of supraventricular tachycardia in pediatric patients. Cardiology. 1999;91:25-30. doi:10.1159/000006873.
2. Saul JP, Scott WA, Brown S, et al. Intravenous Amiodarone Pediatric Investigators. Intravenous amiodarone for incessant tachyarrhythmias in children: a randomized, double-blind, antiarrhythmic drug trial. Circulation. 2005;112:3470-7.
3. Bauersfeld U. RF Ablation in Drug Refractory Cases: When and Whom? Turkish Journal of Arrhythmia, Pacing and Electrophysiology. 2003;1:81-5.
4. Wong KK, Potts JE, Etheridge SP, et al. Medications used to manage supraventricular tachycardia in the infant a North American survey. Pediatr Cardiol. 2006;27:199-203. doi:10.1007/s00246-005-1126-x.
5. Melo SL, Scanavacca MI, Pisani C, et al. Radiofrequency ablation of childhood arrhythmia: observational registry in 125 children. Arq Bras Cardiol. 2012;98:514-8. doi:10.1590/S0066-782X2012005000042.
6. Maid G, Guerchicoff M, Falconi M, et al. Written consent to use the drug in children: the problem of off-label drugs. Curr Pharm Des 2008;14:776-81. doi:10.2174/138161208784007770.
7. Svintsova LI, Kovalev IA, Dzhaffarova OYu, et al. The pecularities of etiology, clinics and treatment of tachyarrhythmias in fetus and children of early age. Pediatria. 2008;87(1):139-42. (In Russ.)
8. Drago F, Leoni L, Bronzetti G, et al. Premature ventricular complexes in children with structurally normal hearts: clinical review and recommendations for diagnosis and treatment. Minerva pediatrica. 2017;69(5):427-33. doi:10.23736/S0026-4946.17.05031-9.
9. Spector ZZ, Seslar SP. Premature ventricular contraction-induced cardiomyopathy in children. Cardiology in the Young. 2016;26(4):711-7. doi:10.1017/S1047951115001110.
10. Tupikina AA, Plotnikova IV, Kovalev IA, et al. Modified Harvard Step Test for exercise tolerance study in healthy children. Siberian Medical Journal. 2015;30(4):36-9. (In Russ.) doi:10.29001/2073-8552-2015-30-4-36-39.
11. Jordan PN, Christini DJ. Therapies for ventricular cardiac arrhythmias. Crit Rev Biomed Eng. 2005;33(6):557-604. doi:10.1615/CritRevBiomedEng.v33.i6.20.
12. Brugada J, Blom N, Sarquella-Brugada G, et al. European Heart Rhythm Association; Association for European Paediatric and Congenital Cardiology. Pharmacological and non-pharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPC-Arrhythmia Working Group joint consensus statement. Europace. 2013;15:1337-82. doi:10.1093/europace/eut082.
13. Chu PY, Hill KD, Clark RH, et al. Treatment of supraventricular tachycardia in infants: Analysis of a large multicenter database. Early Hum Dev 2015;91:345-50. doi:101016/j.earlhumdev.2015.04.001.
14. Timek TA, Dagum P, Lai DT, et al. Pathogenesis of mitral regurgitation in tachycardia-induced cardiomyopathy. Circulation. 2001;104(12)Suppl1):I47-I53. doi:10.1161/hc37t1.094913.
15. Nakazato Y. Tachycardiomyopathy. Indian Pacing Electrophysiol. 2002;2:104-13.
16. Turner CJ, Lau KC, Sholler GF. Outcomes of interventional electrophysiology in children under 2 years of age. Cardiol Young. 2012;22:499-506. doi:10.1017/S1047951111001971.
17. Juneja R, Shah S, Naik N, et al. Management of cardiomyopathy resulting from incessant supraventricular tachycardia in infants and children. Indian Heart. 2002; 54:176-80.
18. Kugler JD. Indication for catheter ablation in infants and children. In: Walsh EP, Saul JP, Triedman JK. Cardiac arrhythmias in children and young adults with congenital heart disease. Philadelphia: Lippincott Williams and Wilkins. 2001; p. 445-61.
19. Umana E, Solares CA, Alpert MA. Tachycardia-induced cardiomyopathy. Am J Med. 2003;114:51-5. doi:10.1016/S0002-9343(02)01472-9.
20. Sun Y, Blom NA, Yu Y, et al. The influence of premature ventricular contractions on left ventricular function in asymptomatic children without structural heart disease: an echocardiographic evaluation. Int J Cardiovasc Imaging. 2003;19:295-9. 10.1023/A:1025418531853.
21. Seslar SP, Garrison MM, Larison C, et al. A multi-institutional analysis of inpatient treatment for supraventricular tachycardia in newborns and infants. Pediatr Cardiol. 2013;34:408-14. doi:10.1007/s00246-012-0474-6.
22. Salerno JC, Kertesz NJ, Friedman RA, et al. Clinical course of atrial ectopic tachycardia is age-dependent: results and treatment in children < 3 or > or =3 years of age. J Am Coll Cardiol. 2004;43:438-44.
23. Knudson JD, Cannon BC, Kim JJ, et al. High-dose sotalol is safe and effective in neonates and infants with refractory supraventricular tachyarrhythmias. Pediatr Cardiol. 2011;32(7):896-903. https://doi.org/10.1007/s00246-011-0010-0.
24. Drago F, Silvetti MS, De Santis A, et al. Paroxysmal reciprocating supraventricular tachycardia in infants: electrophysiologically guided medical treatment and long-term evolution of the re-entry circuit. Europace. 2008;10:629-35. doi:10.1093/europace/eun069.
25. Sanatani S, Potts JE, Reed JH, et al. The study of antiarrhythmic medications in infancy (SAMIS): a multicenter randomized controlled trial comparing the efficacy and safety of digoxin versus propranolol for prophylaxis of supraventricular tachycardia in infants. Circ Arrhythm Electrophysiol. 2012;5:984-91. doi:10.1161/CIRCEP.112.972620.
26. Escudero C, Carr R, Sanatani S. Overview of antiarrhythmic drug therapy for supraventricular tachycardia in children. Prog Pediatr Cardiol. 2013;35:55-63. doi:10.1016/j.ppedcard.2012.11.008.
27. Kim H, Wolff J, Dalal A, et al. Use of intravenous sotalol in newborns with supraventricular tachycardia. HeartRhythm Case Rep. 2017;3:332-5. doi:10.1016/j.hrcr.2017.03.010.
28. Ge H, Li X, Liu H, et al. Predictors of Pharmacological Therapy of Ectopic Atrial Tachycardia in Children. Pediatric cardiology. 2017;38(2):289-95. doi:10.1007/s00246-016-1511-7.
29. Sanatani S, Hamilton RM, Gross GJ. Predictors of refractory tachycardia in infants with supraventricular tachycardia. Pediatr Cardiol. 2002;23:508-12. doi:10.1007/s00246-002-1514-4.
Review
For citations:
Svintsova L.I., Dzhaffarova O.Yu., Plotnikova I.V. Prediction of antiarrhythmic therapy effectiveness in children. Russian Journal of Cardiology. 2019;(7):75-82. https://doi.org/10.15829/1560-4071-2019-7-75-82
Views:
1086
Email this article 